Glucans from the Caripia montagnei mushroom present anti-inflammatory activity.
Caripia montagnei is a basidiomycete species which contains polysaccharides with immunomodulatory properties. An extract of this mushroom underwent removal of the fat content by organic solvent and subsequently proteolysis. The aqueous phase obtained after proteolysis was precipitated with methanol yielding a fraction containing carbohydrates (98.7+/-3.3%) and protein (1.3+/-0.25%). Chemical analysis, infrared spectroscopy and nuclear magnetic resonance (NMR) showed that the carbohydrate fraction contained (63.3+/-4.1) of beta-glucans and proteins (2.2+/-0.3%). These glucans (50mg/kg of body weight) significantly reduced the inflammatory infiltrate produced by thioglycolate-induced peritonitis by 75.5+/-5.2%, when compared to Wy-14643 (60.3+/-6.1%), PFOA (37.8+/-2.8%) and clofibrate (52.2+/-3.2%), p<0.001, which are of the peroxisome proliferator-activated receptor (PPAR-alpha). L-NAME, a nitric oxide synthase inhibitor, reduced the plantar edema in Wistar rats by 91.4+/-1.3% (p<0.001). A significant reduction in nitric oxide (NO) levels was observed in the exudates when the glucans was used in comparison to carrageenan. The C. montagnei glucans did not present signs of inducing cytotoxicity. A decrease in IL-1ra, IL-10 and IFN-gamma in the peritonitis model was observed. Thus, the results suggest that glucans from the C. montagnei mushroom is an effective immunomodulator and may have potential for anti-inflammatory properties.
Queiroz
Lissandra S
LS
Glycobiology Laboratory, Department of Biochemistry, Federal University of Rio Grande do Norte (UFRN), Natal, Brazil.
Nascimento
Marília S
MS
Cruz
Ana K M
AK
Castro
Allisson J G
AJ
Moura
Maria de Fátima V
Mde F
Baseia
Iuri G
IG
Araújo
Renata M
RM
Benevides
Norma M B
NM
Lima
Lucymara F Agnez
LF
Leite
Edda Lisboa
EL
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D001202:Ascitic Fluid / Q000737:chemistry / Q000276:immunology / Q000473:pathology; D001487:Basidiomycota / Q000276:immunology*; D002210:Caprylates / Q000008:administration & dosage / Q000494:pharmacology; D002351:Carrageenan / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects; D002994:Clofibrate / Q000008:administration & dosage / Q000494:pharmacology; D045424:Complex Mixtures / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology*; D005466:Fluorocarbons / Q000008:administration & dosage / Q000494:pharmacology; D005936:Glucans / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D007962:Leukocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D051379:Mice; D009569:Nitric Oxide / Q000032:analysis; D010538:Peritonitis / Q000139:chemically induced / Q000188:drug therapy / Q000276:immunology*; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013864:Thioglycolates / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D002210:Caprylates; D045424:Complex Mixtures; D016207:Cytokines; D005466:Fluorocarbons; D005936:Glucans; D011743:Pyrimidines; D013864:Thioglycolates; D009569:Nitric Oxide; C006253:pirinixic acid; D002351:Carrageenan; C023036:perfluorooctanoic acid; D002994:Clofibrate